Ionis was Metagenomi Therapeutics’s largest revenue line in fiscal 2025, bringing in $24.62M of $25.21M (98%).
| Counterparty Name | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Ionis | $21.92M | $30.44M | $24.62M |
| Moderna Tx, Inc | $18.12M | $18.74M | — |
| Affini-T | $4.72M | $3.11M | $564.00K |
| Other | — | — | $25.00K |
| Total | $44.76M | $52.30M | $25.21M |
Metagenomi Therapeutics brought in $25.21M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. Metagenomi Therapeutics regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $52.30M. Ionis was the largest at $24.62M (97.7%), ahead of Affini-T at $564.00K (2.2%) and Other at $25.00K (0.1%).
Compared with fiscal 2024, Ionis fell 19.1% to $24.62M and Affini-T fell 81.9% to $564.00K.
Metagenomi Therapeutics began breaking out Other in fiscal 2025, when it brought in $25.00K. Metagenomi Therapeutics stopped reporting Moderna Tx, Inc as a separate revenue line after fiscal 2024, when it brought in $18.74M.
Metagenomi Therapeutics (MGX) reports its revenue by counterparty name. In fiscal 2025, Ionis was its largest revenue line, bringing in $24.62M (97.7% of the total), followed by Affini-T at $564.00K (2.2%).
Ionis was Metagenomi Therapeutics' largest revenue line in fiscal 2025, bringing in $24.62M, or 97.7% of the $25.21M total across its three revenue lines.
Every figure comes from Metagenomi Therapeutics' annual financial filings, as reported. Each line keeps the name Metagenomi Therapeutics gives it, and years follow its fiscal calendar.
Metagenomi Therapeutics' revenue by counterparty name goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.